Georgia Medicaid spending on GLP-1 drugs

How much did Georgia Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $52.5 million for GLP-1 drugs paid through Georgia Medicaid in 2025, across at least 59,456 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 76 rows of 283, so these figures are floors.

Pharmacies were reimbursed at least $14.8 million for GLP-1 drugs paid through Georgia Medicaid in 2026 (quarter 1 only, as posted so far), across at least 16,345 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 25 rows of 83, so these figures are floors.

By year and ingredient

2020at least $2,327,005No data$5,663,304at least $2,288,539at least $2,796,959at least $50,443at least $87,033at least $13,213,282
2021at least $4,839,247No dataat least $9,258,880at least $4,269,926at least $1,789,544at least $121,909at least $89,795at least $20,369,301
2022at least $9,554,523at least $289,140at least $12,846,110at least $8,260,292at least $1,341,777$214,210at least $87,741at least $32,593,794
2023at least $17,391,744at least $3,417,488at least $16,229,909at least $13,848,469at least $1,861,435$267,087at least $73,382at least $53,089,514
2024at least $23,152,736at least $4,634,184at least $8,473,591at least $8,843,772at least $1,535,575at least $169,580Suppressedat least $46,809,438
2025at least $31,003,769at least $9,501,724at least $5,081,068at least $6,380,434at least $461,327at least $97,870Suppressedat least $52,526,193
2026 (Q1)at least $9,039,985at least $3,178,821at least $1,318,344at least $1,180,543at least $92,479at least $25,244Suppressedat least $14,835,416

By product, 2025

Ozempicat least $27,753,793at least 28,8068 of 32
Rybelsusat least $1,604,067at least 1,6512 of 26
Wegovyat least $1,645,909at least 1,1899 of 29
Mounjaroat least $9,066,974at least 8,6233 of 51
Zepboundat least $434,750at least 34110 of 19
Liraglutide (generic name listing)at least $2,644,580at least 7,3039 of 39
SaxendaSuppressedSuppressed6 of 6
Victozaat least $2,436,489at least 4,0474 of 12
Trulicityat least $6,380,434at least 6,8043 of 35
Bydureonat least $79,893at least 1063 of 5
Byettaat least $317,582at least 3846 of 9
Exenatide (generic name listing)at least $63,852at least 825 of 7
Soliquaat least $97,870at least 1203 of 8
XultophySuppressedSuppressed5 of 5

By quarter, 2025

Q1 2025at least $12,230,604at least 13,63717 of 67
Q2 2025at least $12,985,891at least 14,55322 of 72
Q3 2025at least $13,517,340at least 15,45017 of 68
Q4 2025at least $13,792,357at least 15,81620 of 76

By quarter, 2026 (posted so far)

Q1 2026at least $14,835,416at least 16,34525 of 83

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.